Merck a leading science and technology company today announced new realworld data that continue to reinforce the JAVELIN Bladder regimen of firstline platinumbased chemotherapy followed by BAVENCIO avelumab maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma UC who do not progress on firstline chemotherapy.